Forest pain drug fails to beat out a placebo in PhII

Three doses of Forest Laboratories' experimental pain drug radiprodil failed to register a significant improvement over a placebo for reducing the level of pain among diabetic patients in a Phase II trial. And Forest along with its partner, Hungary's Gedeon Richter, will go back to the drawing board and see where the program should go from here.

A total of 458 diabetic men and women were recruited for the study and given doses of radiprodil (RGH-896) ranging from 15 mg to 45 mg. But researchers failed to detect a statistically significant response for either the primary or secondary endpoint of reduced pain scores when compared to a placebo. The companies released top-line data only.

"The companies will review the complete study database over the coming weeks to determine the appropriate next steps regarding the development of radiprodil," the developers said in a release. Radiprodil has been in development for a broad range of neuropathic pain conditions, including diabetes.

- check out the Forest release for more info

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.